# Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine

> **NCT00002035** · NA · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 300 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Zidovudine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002035
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1992-04
- **Target enrollment:** 300 (—)
- **Last updated:** 2011-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002035, "Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*